- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| PRAXIS PRECISION MEDICINES Aktie jetzt für 0€ handeln | |||||
| 15.12. | Praxis Precision Medicines stock price target raised to $750 from $250 at Oppenheimer | 2 | Investing.com | ||
| 15.12. | Praxis Precision Medicines: Oppenheimer hebt Kursziel drastisch auf 750 US-Dollar an | 3 | Investing.com Deutsch | ||
| 11.12. | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces Plans to File an NDA for Relutrigine in SCN2A and SCN8A Developmental and Epileptic Encephalopathies in Early 2026 | 188 | GlobeNewswire (Europe) | BOSTON, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies... ► Artikel lesen | |
| 09.12. | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces Alignment with FDA on Simplified and Accelerated Registrational Pathway for Elsunersen in Early Onset SCN2A Developmental and Epileptic Encephalopathy | 141 | GlobeNewswire (Europe) | Clear recognition of high unmet need and urgency for the SCN2A community and plausibility of the mechanism of elsunersen FDA agreed to proposed changes to the EMBRAVE3 trial design to be a single-arm... ► Artikel lesen | |
| 08.12. | Praxis Precision Medicines, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 08.12. | Praxis Precision Medicines stock price target raised to $353 from $251 at TD Cowen | 5 | Investing.com | ||
| 08.12. | Needham hebt Kursziel für Praxis Precision Medicines nach starken Studiendaten an | 8 | Investing.com Deutsch | ||
| 08.12. | Praxis Precision Medicines, Inc.: Praxis AES Wrap-up: Best-in-Class Potential Across Rare Pediatric and Adult Epilepsies | 1 | GlobeNewswire (USA) | ||
| 08.12. | Needham raises Praxis Precision Medicines stock price target on improved data | 1 | Investing.com | ||
| 08.12. | Guggenheim raises Praxis Precision Medicines stock price target to $760 on strong epilepsy data | 5 | Investing.com | ||
| 08.12. | Guggenheim hebt Kursziel für Praxis Precision Medicines nach starken Epilepsie-Daten auf 760 $ an | 18 | Investing.com Deutsch | ||
| 08.12. | Truist Securities raises Praxis Precision Medicines stock price target to $500 | 3 | Investing.com | ||
| 05.12. | Praxis Precision Medicines stock maintains Overweight rating at Piper Sandler | 5 | Investing.com | ||
| 05.12. | Morning Market Movers: SMX, Praxis Precision Medicines, Polyrizon, Rubrik, Inc. See Big Swings | 1.896 | AFX News | HONG KONG (dpa-AFX) - At 7:50 a.m. ET on Friday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| 05.12. | Needham raises Praxis Precision Medicines stock price target to $304 | 3 | Investing.com | ||
| 05.12. | H.C. Wainwright hebt Kursziel für Praxis Precision Medicines nach Studienerfolg auf 340 $ an | 12 | Investing.com Deutsch | ||
| 05.12. | Praxis Precision Soars On Positive Interim Data From EMBOLD Trial | 3 | RTTNews | ||
| 05.12. | Praxis Precision Medicines Stock Surges 25% In Friday Pre-Market Trading- What's Going On? | 2 | Benzinga.com | ||
| 04.12. | Wirksamkeit bestätigt: Aktie von Praxis Precision Medicines steigt nach vorzeitigem Studienabbruch sprunghaft an | 7 | Investing.com Deutsch | ||
| 04.12. | Praxis Precision Medicines kommt Zulassung für Tremor-Medikament näher | 1 | Investing.com Deutsch |
1 2 3 4 5 Weiter >>
99 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 5,388 | +3,10 % | Revolutionäre Fortschritte: BioTech-Ideen für 2026! Bayer, Novo Nordisk, BioNxt, Vidac, BioNTech und Evotec! | Trotz eines schwierigen Umfelds 2025 bleibt der Biotech-Sektor fundamental attraktiv, da der medizinische Fortschritt nicht zum Stillstand kommt. Der rasante Einsatz von Künstlicher Intelligenz und... ► Artikel lesen | |
| QIAGEN | 38,985 | -0,35 % | QIAGEN N.V.: QIAGEN Announces Details for Completion of Synthetic Share Repurchase of up to Approximately $500 Million | Return of approximately $500 million maximum approved by shareholders set to be completed on January 7, 2026 Capital return to be conducted through synthetic share repurchase combines a... ► Artikel lesen | |
| MODERNA | 27,250 | -0,51 % | Moderna, Inc.: CEPI to Fund Pivotal Phase 3 Trial for Moderna's mRNA Pandemic Influenza Vaccine Candidate | Up to $54.3 million CEPI investment aims to help advance Moderna's H5 pandemic influenza vaccine candidate to licensurePartnership strengthens global preparedness against a significant pandemic threatIf... ► Artikel lesen | |
| AMGEN | 280,45 | -0,23 % | ROUNDUP/Aktien New York Schluss: Erholung geht weiter | NEW YORK (dpa-AFX) - Die US-Börsen haben sich am Freitag weiter von ihrem jüngsten Rücksetzer erholt. Eine Jahresendrally sei nach wie vor möglich, sagte ein Investmentexperte. Es herrschte unvermindert... ► Artikel lesen | |
| NOVAVAX | 5,750 | -0,40 % | Novavax, Inc.: Novavax Reports Third Quarter 2025 Financial Results and Operational Highlights | Total revenue of $70 million in the third quarter of 2025
Continued successful execution of Sanofi partnership with $225 million in milestones achieved year-to-date... ► Artikel lesen | |
| BIOGEN | 147,90 | -0,27 % | Biogen Inc.: The Journal of the American Medical Association (JAMA) Neurology Publishes Long Term Results from the QALSODY Phase 3 VALOR Study and its Open-Label Extension in SOD1-ALS | Long-term data published in JAMA Neurology further illustrate the effects of Biogen's QALSODY on function, strength, and survival in SOD1-ALSOver 3 years, a subset of QALSODY-treated participants regained... ► Artikel lesen | |
| ILLUMINA | 115,12 | -0,35 % | MyOme, Inc: Illumina and MyOme Strike Collaboration Deal Including Strategic Investment to Support MyOme's Clinical Trial That Could Save U.S. Healthcare $200 Billion Annually | Partnership unites Illumina's leading sequencing technology with cutting-edge clinical genomics analyses and AI to advance precision medicine for early detection and prevention. SAN DIEGO... ► Artikel lesen | |
| CRISPR THERAPEUTICS | 48,400 | +0,83 % | CRISPR Therapeutics AG: CRISPR Therapeutics Provides Broad Update on Zugocaptagene Geleucel (Zugo-cel; formerly CTX112) in Autoimmune Diseases and Hematologic Malignancies | -Four autoimmune patients treated to date demonstrate deep B-cell depletion sustained for at least 28 days; initial efficacy data suggest significant clinical improvement in patients dosed at the... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 1,810 | -0,55 % | INOVIO Pharmaceuticals, Inc.: INOVIO Reports Third Quarter 2025 Financial Results and Recent Business Highlights | Completed rolling Biologics License Application (BLA) submission seeking accelerated approval for lead candidate INO-3107; requested priority review
Expect... ► Artikel lesen | |
| OCUGEN | 1,185 | -0,59 % | Ocugen, Inc. - 8-K, Current Report | ||
| INTELLIA THERAPEUTICS | 7,964 | -0,18 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Presents Positive Longer-Term Phase 1 Data of Nexiguran Ziclumeran (nex-z) in Patients with Transthyretin (ATTR) Amyloidosis with Cardiomyopathy | One-time treatment of nex-z led to consistently rapid, deep and durable reduction in serum TTR through three years of follow-upConsistent trend in disease stability or improvement in multiple measures... ► Artikel lesen | |
| COSCIENS BIOPHARMA | 1,610 | +1,90 % | COSCIENS Biopharma Inc. Announces Leadership Change | TORONTO, ONTARIO, Nov. 14, 2025 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (TSX: CSCI) (FINRA: CSCIF) ("COSCIENS" or the "Company"), a life science company focused on natural ingredients and pharmaceutical... ► Artikel lesen | |
| EDITAS MEDICINE | 1,857 | +0,19 % | Editas Medicine, Inc.: Editas Medicine Nominates EDIT-401, an LDLR-Targeted Medicine, as Lead In Vivo Development Candidate | EDIT-401 achieved ~90% mean LDL-C reduction with single dose in non-human primates EDIT-401 on track for human proof-of-concept data by end of 2026 Strong cash position with operational runway into... ► Artikel lesen | |
| BIOCRYST PHARMACEUTICALS | 6,528 | +2,29 % | XFRA BO1: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| BIOMARIN PHARMACEUTICAL | 51,56 | -0,58 % | The Biotech Growth Trust PLC - BioMarin Pharmaceuticals to acquire BIOG portfolio company, Amicus Therapeutics | The Biotech Growth Trust PLC - BioMarin Pharmaceuticals to acquire BIOG portfolio company, Amicus Therapeutics
PR Newswire
LONDON, United Kingdom, December 22
For... ► Artikel lesen |
PRAXIS PRECISION MEDICINES INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell -0,48 % bei einem Aktienkurs von 274,42 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu PRAXIS PRECISION MEDICINES INC finden Sie auf Wallstreet Online.